We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

CLK

CLK inhibitors block cell division cycle-like kinases (CLKs), which control pre-mRNA splicing in the nucleus. The four human members, CLK1 to CLK4, are dual-specificity kinases closely related to the DYRK family. They phosphorylate serine/arginine-rich (SR) splicing factors and so change where these factors sit in the nucleus and which splice sites are used. The benzothiazole TG003 was introduced as a CLK inhibitor that shifts alternative splicing in cells. CLK-IN-T3 later revealed a role of CLK activity in exon recognition and in the formation of conjoined gene transcripts. The listed compounds include (E/Z)-TG003, CLK-IN-T3, T025 and the CLK4 inhibitor ML167.

Items 26-27 of 27

  • CLK1/2-IN-2
    Cat. No.
    A54424
    CAS No.
    1005776-20-4

    CLK1/2-IN-2

    CLK1/2-IN-2 is a selective inhibitor of CLK1 and CLK2, demonstrating IC50 values of 1.1 nM and 2.4 nM, respectively. This compound exhibits significant anti-cancer properties, making it a valuable tool for research into cancer biology and therapeutic strategies. Its ability to modulate CLK activity can provide insights into cellular signaling pathways and potential treatment options in cancer research.

    In stock View Details
    5 mg
    $410.00
    10 mg
    $670.00
    All 5 sizes
  • LQ23
    Cat. No.
    A54456
    CAS No.
    2997615-62-8

    LQ23

    LQ23 is a selective inhibitor of CDC2-like kinase 2 (CLK2) with an IC50 value of 1.4 nM. This compound demonstrates notable anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and CLK2-related signaling. It is suitable for studies aimed at elucidating the role of CLK2 in various biological processes and diseases.

    View Details

    Out of stock

    All 3 sizes

Items 26-27 of 27

Added to your cart

View Cart Checkout

    Loading...